WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Various Activities Held to Celebrate 'Pohui' Festival in S China's GuangxiNational Library of China Releases Databases for Dissemination, Study of Ancient BooksInnovative TeaCounty Further Promotes Women's Employment and IncomeChina's School Campuses Resume Liveliness As Spring Semester Kicks OffPeople Enjoy Spring Festival Atmosphere Across ChinaLion Dance Integrated with School Education in Tengxian, S ChinaChinese people pay tributes to legendary ancestorChina Encourages Integrating Intangible Cultural Heritage, TourismChina's Xinjiang to Invest 182 Mln Yuan in Preschool Education
2.6185s , 6505.1328125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,International Interplay news portal